title: [Antiviral therapy of HIV infection in adults].
abstract: BACKGROUND
  Great progress has been made in antiviral treatment of HIV disease over the last few years.
  
  
  METHODS
  The paper is based on relevant literature and our own experience in the largest HIV clinic in Norway.
  
  
  CONCLUSIONS
  Generally speaking, therapy with at least three active drugs is necessary in order to obtain maximum viral suppression. It is not established what constitutes the best starting-point for therapy, or what combination of drugs is the most efficacious. Treatment should be initiated before clinical immunodeficiency develops. All patients with CD4 counts < or = 0.2 x 10(9)/l should be offered treatment. The initial regimen should be either two nucleoside-analogues and one or two protease inhibitors, or two nucleoside-analogues and efavirenz. In order to avoid resistance and treatment failure, the patient should be thoroughly informed before and during treatment about the importance of good compliance.
authors.affiliation: Infeksjonsmedisinsk avdeling Medisinsk divisjon Ullevål sykehus 0407 Oslo. vidar.ormaasen@ioks.uio.no
authors.forename: V
authors.initials: V
authors.lastname: Ormaasen
authors.forename: J N
authors.initials: JN
authors.lastname: Bruun
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D018791:CD4 Lymphocyte Count; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012367:RNA, Viral / Q000032:analysis; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors